Fluphenazine decanoate (BioDeep_00001868394)
Main id: BioDeep_00000006638
代谢物信息卡片
Fluphenazine decanoate
化学式: C32H44F3N3O2S (591.3106)
中文名称: 癸氟奋乃静
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
InChI: InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3
描述信息
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent
Fluphenazine decanoate is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research[1][2][3].
同义名列表
2 个代谢物同义名
数据库引用编号
11 个数据库交叉引用编号
- ChEBI: CHEBI:5124
- KEGG: C07956
- KEGGdrug: D00793
- PubChem: 3388
- ChEMBL: CHEMBL1200854
- CAS: 5002-47-1
- PubChem: 10157
- NIKKAJI: J13.702B
- RefMet: Fluphenazine decanoate
- medchemexpress: HY-B1904
- KNApSAcK: 5124
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Jason D Wagman, Barbara A Wolfe, Mandi W Schook. The effect of fluphenazine decanoate on glucocorticoid production, reproductive cyclicity, and the behavioral stress response in the Persian onager (Equus hemionus onager).
Zoo biology.
2015 Nov; 34(6):525-34. doi:
10.1002/zoo.21250. [PMID: 26491959] - Rachael B Weiss, Mandi W Schook, Barbara A Wolfe. Long-acting neuroleptic use for reproductive management of non-domestic ungulates using the domestic goat (Capra hircus) as a model.
Zoo biology.
2014 May; 33(3):204-11. doi:
10.1002/zoo.21125. [PMID: 24644127] - Sara Costello, Brendan Heffron, Lisa Taddei, Marc Benoit, Laura Hurt, Lindsay Simpson, Jennifer Bishop, Dawn Folker-Calderon, Adam Negrusz. Quantitation of fluphenazine in equine serum following fluphenazine decanoate administration.
Journal of analytical toxicology.
2013 Oct; 37(8):594-9. doi:
10.1093/jat/bkt073. [PMID: 23986099] - John D Baird, Luis G Arroyo, Modest Vengust, M Kimberly J McGurrin, Alexander Rodriguez-Palacios, Daniel G Kenney, Manickam Aravagiri, George A Maylin. Adverse extrapyramidal effects in four horse given fluphenazine decanoate.
Journal of the American Veterinary Medical Association.
2006 Jul; 229(1):104-10. doi:
10.2460/javma.229.1.104. [PMID: 16817724] - Joseph P McEvoy. Risks versus benefits of different types of long-acting injectable antipsychotics.
The Journal of clinical psychiatry.
2006; 67 Suppl 5(?):15-8. doi:
NULL. [PMID: 16822092] - S R Marder, M Aravagiri, W C Wirshing, D A Wirshing, M Lebell, J Mintz. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
Schizophrenia research.
2002 Jan; 53(1-2):25-30. doi:
10.1016/s0920-9964(00)00184-5. [PMID: 11728835] - G S Linn, K Lifshitz, R T O'Keeffe, K Lee, J Camp-Lifshitz. Increased incidence of dyskinesias and other behavioral effects of re-exposure to neuroleptic treatment in social colonies of Cebus apella monkeys.
Psychopharmacology.
2001 Jan; 153(3):285-94. doi:
10.1007/s002130000572. [PMID: 11271400] - M J Gitlin, K H Nuechterlein, J Mintz, D Fogelson, G Bartzokis, J Ventura, K Subotnik, M Aravagiri. Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression.
Psychopharmacology.
2000 Mar; 148(4):350-4. doi:
10.1007/s002130050062. [PMID: 10928306] - J P Luo, J W Hubbard, K K Midha. The roles of depot injection sites and proximal lymph nodes in the presystemic absorption of fluphenazine decanoate and fluphenazine: ex vivo experiments in rats.
Pharmaceutical research.
1998 Sep; 15(9):1485-9. doi:
10.1023/a:1011978327504. [PMID: 9755905] - J P Luo, J W Hubbard, K K Midha. Sensitive method for the simultaneous measurement of fluphenazine decanoate and fluphenazine in plasma by high-performance liquid chromatography with coulometric detection.
Journal of chromatography. B, Biomedical sciences and applications.
1997 Jan; 688(2):303-8. doi:
10.1016/s0378-4347(96)00287-3. [PMID: 9061468] - U Heresco-Levy, D Greenberg, B Lerer, D C Javitt, W A Brown. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
The Israel journal of psychiatry and related sciences.
1997; 34(4):281-9. doi:
NULL. [PMID: 9409085] - R S Miller, G M Peterson, S McLean, T T Westhead, P Gillies. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
Journal of clinical pharmacy and therapeutics.
1995 Apr; 20(2):55-62. doi:
10.1111/j.1365-2710.1995.tb00629.x. [PMID: 7650075] - D C Goff, K K Midha, O Sarid-Segal, J W Hubbard, E Amico. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia.
Psychopharmacology.
1995 Feb; 117(4):417-23. doi:
10.1007/bf02246213. [PMID: 7604142] - W M Glazer, L T Friedhoff, S R Marder, W A Brown. The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection.
Schizophrenia research.
1992 Dec; 8(2):111-7. doi:
10.1016/0920-9964(92)90026-2. [PMID: 1457388] - S D Soni, M Brownlee. Alcohol abuse in chronic schizophrenics: implications for management in the community.
Acta psychiatrica Scandinavica.
1991 Sep; 84(3):272-6. doi:
10.1111/j.1600-0447.1991.tb03143.x. [PMID: 1950628] - S R Marder, K K Midha, T Van Putten, M Aravagiri, E M Hawes, J W Hubbard, G McKay, J Mintz. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
The British journal of psychiatry : the journal of mental science.
1991 May; 158(?):658-65. doi:
10.1192/bjp.158.5.658. [PMID: 1860020] - T Van Putten, S R Marder, W C Wirshing, M Aravagiri, N Chabert. Neuroleptic plasma levels.
Schizophrenia bulletin.
1991; 17(2):197-216. doi:
10.1093/schbul/17.2.197. [PMID: 1679251] - G M Simpson, K G Yadalam, D F Levinson, M J Stephanos, E S Lo, T B Cooper. Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration.
Journal of clinical psychopharmacology.
1990 Dec; 10(6):417-21. doi:
10.1097/00004714-199010060-00007. [PMID: 2286711] - D H Wiles, R G McCreadie, A Whitehead. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
Psychopharmacology.
1990; 101(2):274-81. doi:
10.1007/bf02244140. [PMID: 2349370] - A C Altamura, M C Mauri, T Girardi, B Panetta. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
International journal of clinical pharmacology research.
1990; 10(4):223-8. doi:
. [PMID: 2079381] - G Chouinard, L Annable, W Campbell. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Journal of clinical psychopharmacology.
1989 Aug; 9(4):247-53. doi:
. [PMID: 2570086] - M W Jann, G S Fidone, J M Hernandez, S Amrung, C M Davis. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
Psychiatry research.
1989 May; 28(2):153-9. doi:
10.1016/0165-1781(89)90043-7. [PMID: 2568651] - W M Glazer. Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia.
Schizophrenia research.
1988 Nov; 1(6):425-9. doi:
10.1016/0920-9964(88)90025-4. [PMID: 3154530] - T Kitamura, D A McGovern, N W Imlah, D Wiles, A A Schiff. Plasma levels of fluphenazine and prolactin in psychiatric patients.
European archives of psychiatry and neurological sciences.
1988 Sep; 237(6):320-6. doi:
10.1007/bf00380974. [PMID: 3181218] - S D Soni, D Wiles, A A Schiff, J S Bamrah. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
The British journal of psychiatry : the journal of mental science.
1988 Sep; 153(?):382-4. doi:
10.1192/bjp.153.3.382. [PMID: 3250675] - R A Boza, F Milanes, T Starkey, V Slater, F Dominguez. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
The Journal of clinical psychiatry.
1988 Jun; 49(6):245. doi:
NULL. [PMID: 2897960] - S G Siris, A P Sellew, K Frechen, T B Cooper, J Mandell, E Casey. Antidepressants in the treatment of post-psychotic depression in schizophrenia: drug interactions and other considerations.
Clinical chemistry.
1988 May; 34(5):837-40. doi:
NULL. [PMID: 3286051] - S G Siris, F Adan, A Lee, T B Cooper, J Mandeli, E Casey. Patterns of plasma imipramine-desipramine concentrations in patients receiving concomitant fluphenazine decanoate.
The Journal of clinical psychiatry.
1988 Feb; 49(2):64-5. doi:
. [PMID: 3338977] - M J Gitlin, K K Midha, D Fogelson, K Nuechterlein. Persistence of fluphenazine in plasma after decanoate withdrawal.
Journal of clinical psychopharmacology.
1988 Feb; 8(1):53-6. doi:
. [PMID: 3351000] - S G Siris, A Strahan, J Mandeli, T B Cooper, E Casey. Fluphenazine decanoate dose and severity of depression in patients with post-psychotic depression.
Schizophrenia research.
1988 Jan; 1(1):31-5. doi:
10.1016/0920-9964(88)90037-0. [PMID: 3154504] - A Viala, B Ba, A Durand, F Gouezo, N Hou, A Jørgensen. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.
Psychopharmacology.
1988; 94(3):293-7. doi:
10.1007/bf00174677. [PMID: 2895936] - D T Martin, M Swash. Muscle pathology in the neuroleptic malignant syndrome.
Journal of neurology.
1987 Dec; 235(2):120-1. doi:
10.1007/bf00718024. [PMID: 3430190] - T G Dinan. Neuroleptic effects on platelet aggregation: a study in normal volunteers and schizophrenics.
Psychological medicine.
1987 Nov; 17(4):875-81. doi:
10.1017/s0033291700000672. [PMID: 2893407] - R A Prysor-Jones, J J Silverlight, J S Jenkins. Hyperprolactinemia reduces vasoactive intestinal peptide in the anterior pituitary glands of rats.
Neuroscience letters.
1987 Oct; 80(3):333-8. doi:
10.1016/0304-3940(87)90477-0. [PMID: 3683988] - T R Norman, P F Marriott, N M Kimber, G D Burrows. Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.
International clinical psychopharmacology.
1987 Oct; 2(4):299-305. doi:
10.1097/00004850-198710000-00002. [PMID: 3693869] - J P McKane, A D Robinson, D H Wiles, R G McCreadie, G S Stirling. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
The British journal of psychiatry : the journal of mental science.
1987 Sep; 151(?):333-6. doi:
10.1192/bjp.151.3.333. [PMID: 3322467] - J Turbott, J Villiger, L Hunter. Depot neuroleptic medication and serum levels by radioreceptor assay: prolactin concentration, electrocardiogram abnormalities and six-month outcome.
The Australian and New Zealand journal of psychiatry.
1987 Sep; 21(3):327-38. doi:
10.1080/00048678709160929. [PMID: 3435373] - J C Levron, R Ropert. [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics].
L'Encephale.
1987 Mar; 13(2):83-7. doi:
. [PMID: 2885172] - P Achkova. [Possibilities for research on the proton-acceptor action of drug preparations].
Eksperimentalna meditsina i morfologiia.
1987; 26(3):1-5. doi:
". [PMID: 2822373] - K K Midha, J W Hubbard, S R Marder, E M Hawes, T Van Putten, G McKay, P R May. The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.
Psychopharmacology.
1987; 93(3):369-73. doi:
10.1007/bf00187259. [PMID: 3124166] - F Brambilla, F Facchinetti, F Petraglia, E Smeraldi, L Bellodi, V Brancato, A R Genazzani. Effects of neuroleptic treatments on peripheral opioid secretion.
Neuropsychobiology.
1987; 18(2):68-73. doi:
10.1159/000118395. [PMID: 2897644] - G Jayaram, J Coyle, L Tune. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
The Journal of clinical psychiatry.
1986 May; 47(5):247-8. doi:
NULL. [PMID: 3700342] - S R Marder, E M Hawes, T Van Putten, J W Hubbard, G McKay, J Mintz, P R May, K K Midha. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.
Psychopharmacology.
1986; 88(4):480-3. doi:
10.1007/bf00178510. [PMID: 3085136] - S R Marder, J W Hubbard, T Van Putten, E M Hawes, G McKay, J Mintz, P R May, K K Midha. Plasma fluphenazine levels in patients receiving two doses of fluphenazine decanoate.
Psychopharmacology bulletin.
1986; 22(1):264-6. doi:
NULL. [PMID: 3726072] - B M Cohen, C Waternaux, G Chouinard, B R Sommer, B Jones. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Journal of clinical psychopharmacology.
1985 Dec; 5(6):328-32. doi:
. [PMID: 4066997] - M W Jann, L Ereshefsky, S R Saklad. Clinical pharmacokinetics of the depot antipsychotics.
Clinical pharmacokinetics.
1985 Jul; 10(4):315-33. doi:
10.2165/00003088-198510040-00003. [PMID: 2864156] - W A Brown, M A Silver. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Journal of clinical psychopharmacology.
1985 Jun; 5(3):143-7. doi:
NULL. [PMID: 3998204] - G M Simpson, K Yadalam. Blood levels of neuroleptics: state of the art.
The Journal of clinical psychiatry.
1985 May; 46(5 Pt 2):22-8. doi:
NULL. [PMID: 2859277] - W Kissling, H J Möller, K Walter, B Wittmann, R Krueger, D Trenk. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Pharmacopsychiatry.
1985 May; 18(3):240-5. doi:
10.1055/s-2007-1017373. [PMID: 4011672] - A C Altamura, S H Curry, S Montgomery, D H Wiles. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.
Psychopharmacology.
1985; 87(1):30-3. doi:
10.1007/bf00431773. [PMID: 3933035] - T Gift, K Plum, M Price. Depot fluphenazine and plasma prolactin.
Progress in neuro-psychopharmacology & biological psychiatry.
1985; 9(4):407-12. doi:
10.1016/0278-5846(85)90194-0. [PMID: 4070643] - S S Chang, J I Javaid, M W Dysken, R C Casper, P G Janicak, J M Davis. Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia.
Psychopharmacology.
1985; 87(1):55-8. doi:
10.1007/bf00431778. [PMID: 3933037] - L Ereshefsky, S R Saklad, M W Jann, C M Davis, A Richards, D R Seidel. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.
The Journal of clinical psychiatry.
1984 May; 45(5 Pt 2):50-9. doi:
NULL. [PMID: 6143748] - S J Dencker. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
The Journal of clinical psychiatry.
1984 May; 45(5 Pt 2):22-7. doi:
NULL. [PMID: 6143744] - A Viala, N Hou, B Ba, A Durand, H Dufour, N D'Agostino, C Berda, A Jørgensen. Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.
Psychopharmacology.
1984; 83(2):147-50. doi:
10.1007/bf00429723. [PMID: 6146995] - J E Granato, B J Stern, A Ringel, A H Karim, A Krumholz, J Coyle, S Adler. Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine.
Annals of neurology.
1983 Jul; 14(1):89-90. doi:
10.1002/ana.410140117. [PMID: 6614876] - T R Barnes, D H Wiles. Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment.
Psychopharmacology.
1983; 81(4):359-62. doi:
10.1007/bf00427579. [PMID: 6140703] - Z Merali, G Toth. Effects of fluphenazine decanoate (a long-acting phenothiazine) on serum prolactin and amphetamine-induced behavioural changes.
Pharmacology, biochemistry, and behavior.
1982 Jul; 17(1):25-30. doi:
10.1016/0091-3057(82)90257-x. [PMID: 7122665] - R McCreadie, M Mackie, D Morrison, J Kidd. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
The British journal of psychiatry : the journal of mental science.
1982 Mar; 140(?):280-6. doi:
10.1192/bjp.140.3.280. [PMID: 7093596] - S G Siris, T B Cooper, A E Rifkin, R Brenner, J A Lieberman. Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.
The American journal of psychiatry.
1982 Jan; 139(1):104-6. doi:
10.1176/ajp.139.1.104. [PMID: 7055248] - D J Goode, H Y Meltzer, V S Fang. Daytime variation in serum prolactin level in patients receiving oral and depot antipsychotic medication.
Biological psychiatry.
1981 Jul; 16(7):653-62. doi:
NULL. [PMID: 7196775] - M Arató, A Erdös, M Polgár. Endocrinological changes in patients with sexual dysfunction under long-term neuroleptic treatment.
Pharmakopsychiatrie, Neuro-Psychopharmakologie.
1979 Nov; 12(6):426-31. doi:
10.1055/s-0028-1094639. [PMID: 538087] - A C Altamura, R Whelpton, S H Curry. Animal model for investigation of fluphenazine kinetics after administration of long-acting esters.
Biopharmaceutics & drug disposition.
1979 Oct; 1(2):65-72. doi:
10.1002/bdd.2510010204. [PMID: 552863] - J E Groves, M R Mandel. The long-acting phenothiazines.
Archives of general psychiatry.
1975 Jul; 32(7):893-900. doi:
10.1001/archpsyc.1975.01760250085009. [PMID: 239663]
